Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | ALG6 | CTRPv2 | pan-cancer | AAC | 0.15 | 3e-06 |
mRNA | TTF1 | CTRPv2 | pan-cancer | AAC | 0.16 | 3e-06 |
mRNA | FOXI3 | CTRPv2 | pan-cancer | AAC | 0.15 | 3e-06 |
mRNA | ASB14 | CTRPv2 | pan-cancer | AAC | 0.16 | 3e-06 |
mRNA | REEP5 | CTRPv2 | pan-cancer | AAC | -0.18 | 3e-06 |
mRNA | LEMD3 | CTRPv2 | pan-cancer | AAC | 0.15 | 3e-06 |
mRNA | DCAKD | CTRPv2 | pan-cancer | AAC | 0.15 | 3e-06 |
mRNA | ZNF784 | CTRPv2 | pan-cancer | AAC | 0.15 | 3e-06 |
mRNA | EFNA2 | CTRPv2 | pan-cancer | AAC | 0.16 | 3e-06 |
mRNA | TOP2A | CTRPv2 | pan-cancer | AAC | 0.16 | 3e-06 |